Table of Contents
Advances in Hepatology
Volume 2014 (2014), Article ID 498369, 14 pages
http://dx.doi.org/10.1155/2014/498369
Review Article

Targeting Hepatic Glycerolipid Synthesis and Turnover to Treat Fatty Liver Disease

Washington University School of Medicine, St. Louis, MO 63110, USA

Received 5 January 2014; Accepted 3 March 2014; Published 10 April 2014

Academic Editor: Stefano Bellentani

Copyright © 2014 George G. Schweitzer and Brian N. Finck. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. M. Clark and A. M. Diehl, “Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis,” Journal of the American Medical Association, vol. 289, no. 22, pp. 3000–3004, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. J. M. Clark, F. L. Brancati, and A. M. Diehl, “Nonalcoholic fatty liver disease,” Gastroenterology, vol. 122, no. 6, pp. 1649–1657, 2002. View at Google Scholar · View at Scopus
  3. W. Youssef and A. J. McCullough, “Diabetes mellitus, obesity, and hepatic steatosis,” Seminars in Gastrointestinal Disease, vol. 13, no. 1, pp. 17–30, 2002. View at Google Scholar · View at Scopus
  4. W. I. Youssef and A. J. McCullough, “Steatohepatitis in obese individuals,” Bailliere's Best Practice and Research in Clinical Gastroenterology, vol. 16, no. 5, pp. 733–747, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. J. D. Browning and J. D. Horton, “Molecular mediators of hepatic steatosis and liver injury,” Journal of Clinical Investigation, vol. 114, no. 2, pp. 147–152, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. J. D. Browning, L. S. Szczepaniak, R. Dobbins et al., “Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity,” Hepatology, vol. 40, no. 6, pp. 1387–1395, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Begriche, A. Igoudjil, D. Pessayre, and B. Fromenty, “Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it,” Mitochondrion, vol. 6, no. 1, pp. 1–38, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. I. R. Wanless and K. Shiota, “The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis,” Seminars in Liver Disease, vol. 24, no. 1, pp. 99–106, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Te Sligte, I. Bourass, J. P. Sels, A. Driessen, R. W. Stockbrugger, and G. H. Koek, “Non-alcoholic steatohepatitis: review of a growing medical problem,” European Journal of Internal Medicine, vol. 15, no. 1, pp. 10–21, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Garcia-Ruiz, A. Colell, A. Morales, N. Kaplowitz, and J. C. Fernandez-Checa, “Role of oxidative stress generated from the mitochondrial electron transport chain and mitochondrial glutathione status in loss of mitochondrial function and activation of transcription factor nuclear factor-κB: studies with isolated mitochondria and rat hepatocytes,” Molecular Pharmacology, vol. 48, no. 5, pp. 825–834, 1995. View at Google Scholar · View at Scopus
  11. B. Fromenty, M. A. Robin, A. Igoudjil, A. Mansouri, and D. Pessayre, “The ins and outs of mitochondrial dysfunction in NASH,” Diabetes and Metabolism, vol. 30, no. 2, pp. 121–138, 2004. View at Google Scholar · View at Scopus
  12. A. J. Sanyal, C. Campbell-Sargent, F. Mirshahi et al., “Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities,” Gastroenterology, vol. 120, no. 5, pp. 1183–1192, 2001. View at Google Scholar · View at Scopus
  13. S. H. Caldwell, R. H. Swerdlow, E. M. Khan et al., “Mitochondrial abnormalities in non-alcoholic steatohepatitis,” Journal of Hepatology, vol. 31, no. 3, pp. 430–434, 1999. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Klein, B. Mittendorfer, J. C. Eagon et al., “Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease,” Gastroenterology, vol. 130, no. 6, pp. 1564–1572, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. S. W. Coppack, D. L. Chinkes, J. M. Miles, B. W. Patterson, and S. Klein, “A multicompartmental model of in vivo adipose tissue glycerol kinetics and capillary permeability in lean and obese humans,” Diabetes, vol. 54, no. 7, pp. 1934–1941, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. S. W. Coppack, J. F. Horowitz, D. S. Paramore, P. E. Cryer, H. D. Royal, and S. Klein, “Whole body, adipose tissue, and forearm norepinephrine kinetics in lean and obese women,” American Journal of Physiology—Endocrinology and Metabolism, vol. 275, no. 5, pp. E830–E834, 1998. View at Google Scholar · View at Scopus
  17. R. R. Townsend and S. Klein, “Lipolytic sensitivity and response to fasting in normotensive and hypertensive obese humans,” Metabolism: Clinical and Experimental, vol. 46, no. 9, pp. 1080–1084, 1997. View at Publisher · View at Google Scholar · View at Scopus
  18. B. Mittendorfer, B. W. Patterson, S. Klein, and L. S. Sidossis, “VLDL-triglyceride kinetics during hyperglycemia-hyperinsulinemia: effects of sex and obesity,” American Journal of Physiology—Endocrinology and Metabolism, vol. 284, no. 4, pp. E708–E715, 2003. View at Google Scholar · View at Scopus
  19. B. Mittendorfer, B. W. Patterson, and S. Klein, “Effect of weight loss on VLDL-triglyceride and apoB-100 kinetics in women with abdominal obesity,” American Journal of Physiology—Endocrinology and Metabolism, vol. 284, no. 3, pp. E549–E556, 2003. View at Google Scholar · View at Scopus
  20. I. Shimomura, M. Matsuda, R. E. Hammer, Y. Bashmakov, M. S. Brown, and J. L. Goldstein, “Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice,” Molecular Cell, vol. 6, no. 1, pp. 77–86, 2000. View at Google Scholar · View at Scopus
  21. Y. Shi and D. Cheng, “Beyond triglyceride synthesis: the dynamic functional roles of MGAT and DGAT enzymes in energy metabolism,” American Journal of Physiology—Endocrinology and Metabolism, vol. 297, no. 1, pp. E10–E18, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Cao, E. Hawkins, J. Brozinick et al., “A predominant role of Acyl-CoA:monoacylglycerol acyltransferase-2 in dietary fat absorption implicated by tissue distribution, subcellular localization, and up-regulation by high fat diet,” Journal of Biological Chemistry, vol. 279, no. 18, pp. 18878–18886, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. F. Wilfling, H. Wang, J. T. Haas et al., “Triacylglycerol synthesis enzymes mediate lipid droplet growth by relocalizing from the ER to lipid droplets,” Developmental Cell, vol. 24, no. 4, pp. 384–399, 2013. View at Google Scholar
  24. B. R. Bacon, M. J. Farahvash, C. G. Janney, and B. A. Neuschwander-Tetri, “Nonalcoholic steatohepatitis: an expanded clinical entity,” Gastroenterology, vol. 107, no. 4, pp. 1103–1109, 1994. View at Google Scholar · View at Scopus
  25. M. J. Contos, J. Choudhury, A. S. Mills, and A. J. Sanyal, “The histologic spectrum of nonalcoholic fatty liver disease,” Clinics in Liver Disease, vol. 8, no. 3, pp. 481–500, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. B. Fromenty, A. Berson, and D. Pessayre, “Microvesicular steatosis and steatohepatitis: role of mitochondrial dysfunction and lipid peroxidation,” Journal of Hepatology, Supplement, vol. 26, no. 1, pp. 13–22, 1997. View at Google Scholar · View at Scopus
  27. E. Freneaux, G. Labbe, P. Letteron et al., “Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: possible role in microvesicular steatosis induced by this antibiotic,” Hepatology, vol. 8, no. 5, pp. 1056–1062, 1988. View at Google Scholar · View at Scopus
  28. A. D. Burt, A. Mutton, and C. P. Day, “Diagnosis and interpretation of steatosis and steatohepatitis,” Seminars in Diagnostic Pathology, vol. 15, no. 4, pp. 246–258, 1998. View at Google Scholar · View at Scopus
  29. A. M. Hall, E. M. Brunt, Z. Chen et al., “Dynamic and differential regulation of proteins that coat lipid droplets in fatty liver dystrophic mice,” Journal of Lipid Research, vol. 51, no. 3, pp. 554–563, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. C. Zhang, A. A. Wendel, M. R. Keogh, T. E. Harris, J. Chen, and R. A. Coleman, “Glycerolipid signals alter mTOR complex 2 (mTORC2) to diminish insulin signaling,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 5, pp. 1667–1672, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. O. Bezy, T. T. Tran, J. Pihlajamäki et al., “PKCδ regulates hepatic insulin sensitivity and hepatosteatosis in mice and humans,” Journal of Clinical Investigation, vol. 121, no. 6, pp. 2504–2517, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. V. T. Samuel, Z.-X. Liu, A. Wang et al., “Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease,” Journal of Clinical Investigation, vol. 117, no. 3, pp. 739–745, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. G.-S. Han, W.-I. Wu, and G. M. Carman, “The Saccharomyces cerevisiae lipin homolog is a Mg2+-dependent phosphatidate phosphatase enzyme,” Journal of Biological Chemistry, vol. 281, no. 14, pp. 9210–9218, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. A. A. Wendel, T. M. Lewin, and R. A. Coleman, “Glycerol-3-phosphate acyltransferases: rate limiting enzymes of triacylglycerol biosynthesis,” Biochimica et Biophysica Acta—Molecular and Cell Biology of Lipids, vol. 1791, no. 6, pp. 501–506, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. A. A. Wendel, D. E. Cooper, O. R. Ilkayeva, D. M. Muoio, and R. A. Coleman, “Glycerol-3-phosphate acyltransferase (GPAT)-1, but not GPAT4, incorporates newly synthesized fatty acids into triacylglycerol and diminishes fatty acid oxidation,” The Journal of Biological Chemistry, vol. 288, no. 38, pp. 27299–27306, 2013. View at Google Scholar
  36. C. A. Nagle, J. An, M. Shiota et al., “Hepatic overexpression of glycerol-sn-3-phosphate acyltransferase 1 in rats causes insulin resistance,” Journal of Biological Chemistry, vol. 282, no. 20, pp. 14807–14815, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Neschen, K. Morino, L. E. Hammond et al., “Prevention of hepatic steatosis and hepatic insulin resistance in mitochondrial acyl-CoA:glycerol-sn-3-phosphate acyltransferase 1 knockout mice,” Cell Metabolism, vol. 2, no. 1, pp. 55–65, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. L. E. Hammond, P. A. Gallagher, S. Wang et al., “Mitochondrial glycerol-3-phosphate acyltransferase-deficient mice have reduced weight and liver triacylglycerol content and altered glycerolipid fatty acid composition,” Molecular and Cellular Biology, vol. 22, no. 23, pp. 8204–8214, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Yazdi, A. Ahnmark, L. William-Olsson et al., “The role of mitochondrial glycerol-3-phosphate acyltransferase-1 in regulating lipid and glucose homeostasis in high-fat diet fed mice,” Biochemical and Biophysical Research Communications, vol. 369, no. 4, pp. 1065–1070, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. A. A. Wendel, L. O. Li, Y. Li, G. W. Cline, G. I. Shulman, and R. A. Coleman, “Glycerol-3-phosphate acyltransferase 1 deficiency in ob/ob mice diminishes hepatic steatosis but does not protect against insulin resistance or obesity,” Diabetes, vol. 59, no. 6, pp. 1321–1329, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. H. Xu, D. Wilcox, P. Nguyen et al., “Hepatic knockdown of mitochondrial GPAT1 in ob/ob mice improves metabolic profile,” Biochemical and Biophysical Research Communications, vol. 349, no. 1, pp. 439–448, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. R. E. Gimeno and J. Cao, “Mammalian glycerol-3-phosphate acyltransferases: new genes for an old activity,” Journal of Lipid Research, vol. 49, no. 10, pp. 2079–2088, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. C. A. Nagle, L. Vergnes, H. Dejong et al., “Identification of a novel sn-glycerol-3-phosphate acyltransferase isoform, GPAT4, as the enzyme deficient in Agpat6-/- mice,” Journal of Lipid Research, vol. 49, no. 4, pp. 823–831, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. L. Vergnes, A. P. Beigneux, R. Davis, S. M. Watkins, S. G. Young, and K. Reue, “Agpat6 deficiency causes subdermal lipodystrophy and resistance to obesity,” Journal of Lipid Research, vol. 47, no. 4, pp. 745–754, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Kumari, G. Schoiswohl, C. Chitraju et al., “Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase,” Cell Metabolism, vol. 15, no. 5, pp. 691–702, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. D. W. Leung, “The structure and functions of human lysophosphatidic acid acyltransferases,” Front Biosci, vol. 6, pp. D944–D953, 2001. View at Google Scholar · View at Scopus
  47. V. A. Cortés, D. E. Curtis, S. Sukumaran et al., “Molecular mechanisms of hepatic steatosis and insulin resistance in the AGPAT2-deficient mouse model of congenital generalized lipodystrophy,” Cell Metabolism, vol. 9, no. 2, pp. 165–176, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. A. K. Agarwal, E. Arioglu, S. De Almeida et al., “AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34,” Nature Genetics, vol. 31, no. 1, pp. 21–23, 2002. View at Publisher · View at Google Scholar · View at Scopus
  49. J. Donkor, M. Sariahmetoglu, J. Dewald, D. N. Brindley, and K. Reue, “Three mammalian lipins act as phosphatidate phosphatases with distinct tissue expression patterns,” Journal of Biological Chemistry, vol. 282, no. 6, pp. 3450–3457, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. H. Ren, L. Federico, H. Huang et al., “A phosphatidic acid binding/nuclear localization motif determines lipin1 function in lipid metabolism and adipogenesis,” Molecular Biology of the Cell, vol. 21, no. 18, pp. 3171–3181, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. B. N. Finck, M. C. Gropler, Z. Chen et al., “Lipin 1 is an inducible amplifier of the hepatic PGC-1α/PPARα regulatory pathway,” Cell Metabolism, vol. 4, no. 3, pp. 199–210, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. T. E. Harris, T. A. Huffman, A. Chi et al., “Insulin controls subcellular localization and multisite phosphorylation of the phosphatidic acid phosphatase, lipin 1,” Journal of Biological Chemistry, vol. 282, no. 1, pp. 277–286, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. M. C. Gropler, T. E. Harris, A. M. Hall et al., “Lipin 2 is a liver-enriched phosphatidate phosphohydrolase enzyme that is dynamically regulated by fasting andobesity in mice,” Journal of Biological Chemistry, vol. 284, no. 11, pp. 6763–6772, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Hu, F. Wang, X. Li et al., “Regulation of hepatic lipin-1 by ethanol: role of AMP-activated protein kinase/sterol regulatory element-binding protein 1 signaling in mice,” Hepatology, vol. 55, no. 2, pp. 437–446, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Hu, H. Yin, M. S. Mitra et al., “Hepatic-specific lipin-1 deficiency exacerbates experimental alcohol-induced steatohepatitis in mice,” Hepatology, vol. 58, no. 6, pp. 1953–1963, 2013. View at Google Scholar
  56. Z. Chen, M. C. Gropler, J. Norris, J. C. Lawrence Jr., T. E. Harris, and B. N. Finck, “Alterations in hepatic metabolism in fld mice reveal a role for lipin 1 in regulating VLDL-triacylglyceride secretion,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 10, pp. 1738–1744, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. A. Zeharia, A. Shaag, R. H. Houtkooper et al., “Mutations in LPIN1 cause recurrent acute myoglobinuria in childhood,” American Journal of Human Genetics, vol. 83, no. 4, pp. 489–494, 2008. View at Publisher · View at Google Scholar · View at Scopus
  58. C. Michot, L. Hubert, M. Brivet et al., “LPIN1 gene mutations: a major cause of severe rhabdomyolysis in early childhood,” Human Mutation, vol. 31, no. 7, pp. E1564–E1573, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. C. Michot, L. Hubert, N. B. Romero et al., “Study of LPIN1, LPIN2 and LPIN3 in rhabdomyolysis and exercise-induced myalgia,” Journal of Inherited Metabolic Disease, vol. 35, no. 6, pp. 1119–1128, 2012. View at Publisher · View at Google Scholar · View at Scopus
  60. V. Nobili, B. Donati, N. Panera et al., “A Four-polymorphisms risk score predicts steatohepatitis in children with non-alcoholic fatty liver disease,” Journal of Pediatric Gastroenterology and Nutrition. In press.
  61. L. Valenti, B. M. Motta, A. Alisi et al., “LPIN1 rs13412852 polymorphism in pediatric nonalcoholic fatty liver disease,” Journal of Pediatric Gastroenterology and Nutrition, vol. 54, no. 5, pp. 588–593, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. D. Ryu, K.-J. Oh, H.-Y. Jo et al., “TORC2 regulates hepatic insulin signaling via a mammalian phosphatidic acid phosphatase, LIPIN1,” Cell Metabolism, vol. 9, no. 3, pp. 240–251, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. M. A. Croce, J. C. Eagon, L. L. LaRiviere, K. M. Korenblat, S. Klein, and B. N. Finck, “Hepatic lipin 1β expression is diminished in insulin-resistant obese subjects and is reactivated by marked weight loss,” Diabetes, vol. 56, no. 9, pp. 2395–2399, 2007. View at Publisher · View at Google Scholar · View at Scopus
  64. J. Donkor, P. Zhang, S. Wong et al., “A conserved serine residue is required for the phosphatidate phosphatase activity but not the transcriptional coactivator functions of lipin-1 and lipin-2,” Journal of Biological Chemistry, vol. 284, no. 43, pp. 29968–29978, 2009. View at Publisher · View at Google Scholar · View at Scopus
  65. J. R. Dwyer, J. Donkor, P. Zhang et al., “Mouse lipin-1 and lipin-2 cooperate to maintain glycerolipid homeostasis in liver and aging cerebellum,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 37, pp. E2486–E2495, 2012. View at Google Scholar
  66. D. Ryu, W.-Y. Seo, Y.-S. Yoon et al., “Endoplasmic reticulum stress promotes LIPIN2-dependent hepatic insulin resistance,” Diabetes, vol. 60, no. 4, pp. 1072–1081, 2011. View at Publisher · View at Google Scholar · View at Scopus
  67. Y. G. Yue, Y. Q. Chen, Y. Zhang et al., “The acyl coenzymeA:monoacylglycerol acyltransferase 3 (MGAT3) gene is a pseudogene in mice but encodes a functional enzyme in rats,” Lipids, vol. 46, no. 6, pp. 513–520, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. A. M. Hall, K. Kou, Z. Chen et al., “Evidence for regulated monoacylglycerol acyltransferase expression and activity in human liver,” Journal of Lipid Research, vol. 53, no. 5, pp. 990–999, 2012. View at Publisher · View at Google Scholar · View at Scopus
  69. C.-L. E. Yen, S. J. Stone, S. Cases, P. Zhou, and R. V. Farese Jr., “Identification of a gene encoding MGAT1, a monoacylglycerol acyltransferase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 13, pp. 8512–8517, 2002. View at Publisher · View at Google Scholar · View at Scopus
  70. C.-L. E. Yen and R. V. Farese Jr., “MGAT2, a monoacylglycerol acyltransferase expressed in the small intestine,” Journal of Biological Chemistry, vol. 278, no. 20, pp. 18532–18537, 2003. View at Publisher · View at Google Scholar · View at Scopus
  71. Y. J. Lee, E. H. Ko, J. E. Kim et al., “Nuclear receptor PPARgamma-regulated monoacylglycerol O-acyltransferase 1 (MGAT1) expression is responsible for the lipid accumulation in diet-induced hepatic steatosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 34, pp. 13656–13661, 2012. View at Google Scholar
  72. A. M. Hall, N. Soufi, K. T. Chambers et al., “Abrogating monoacylglycerol acyltransferase activity in liver improves glucose tolerance and hepatic insulin signaling in obese mice,” Diabetes, 2014. View at Publisher · View at Google Scholar
  73. C.-L. E. Yen, M.-L. Cheong, C. Grueter et al., “Deficiency of the intestinal enzyme acyl CoA:monoacylglycerol acyltransferase-2 protects mice from metabolic disorders induced by high-fat feeding,” Nature Medicine, vol. 15, no. 4, pp. 442–446, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. Y. Gao, D. W. Nelson, T. Banh, M. I. Yen, and C. L. Yen, “Intestine-specific expression of MOGAT2 partially restores metabolic efficiency in Mogat2-deficient mice,” The Journal of Lipid Research, vol. 54, no. 6, pp. 1644–1652, 2013. View at Google Scholar
  75. S. J. Smith, S. Cases, D. R. Jensen et al., “Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat,” Nature Genetics, vol. 25, no. 1, pp. 87–90, 2000. View at Publisher · View at Google Scholar · View at Scopus
  76. C. J. Villanueva, M. Monetti, M. Shih et al., “Specific role for acyl CoA:diacylglycerol acyltransferase 1 (Dgat1) in hepatic steatosis due to exogenous fatty acids,” Hepatology, vol. 50, no. 2, pp. 434–442, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. H. C. Chen, S. J. Smith, Z. Ladha et al., “Increased insulin and leptin sensitivity in mice lacking acyl CoA:diacylglycerol acyltransferase 1,” Journal of Clinical Investigation, vol. 109, no. 8, pp. 1049–1055, 2002. View at Publisher · View at Google Scholar · View at Scopus
  78. S. C. Cheol, D. B. Savage, A. Kulkarni et al., “Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance,” Journal of Biological Chemistry, vol. 282, no. 31, pp. 22678–22688, 2007. View at Publisher · View at Google Scholar · View at Scopus
  79. K. Yamaguchi, L. Yang, S. McCall et al., “Diacylglycerol acyltranferase 1 anti-sense oligonucleotides reduce hepatic fibrosis in mice with nonalcoholic steatohepatitis,” Hepatology, vol. 47, no. 2, pp. 625–635, 2008. View at Publisher · View at Google Scholar · View at Scopus
  80. E. Herker, C. Harris, C. Hernandez et al., “Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1,” Nature Medicine, vol. 16, no. 11, pp. 1295–1298, 2010. View at Publisher · View at Google Scholar · View at Scopus
  81. C. Harris, E. Herker, R. V. Farese Jr., and M. Ott, “Hepatitis C virus core protein decreases lipid droplet turnover: a mechanism for core-induced steatosis,” Journal of Biological Chemistry, vol. 286, no. 49, pp. 42615–42625, 2011. View at Publisher · View at Google Scholar · View at Scopus
  82. S. J. Stone, H. M. Myers, S. M. Watkins et al., “Lipopenia and skin barrier abnormalities in DGAT2-deficient mice,” Journal of Biological Chemistry, vol. 279, no. 12, pp. 11767–11776, 2004. View at Publisher · View at Google Scholar · View at Scopus
  83. X. X. Yu, S. F. Murray, S. K. Pandey et al., “Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice,” Hepatology, vol. 42, no. 2, pp. 362–371, 2005. View at Publisher · View at Google Scholar · View at Scopus
  84. K. Yamaguchi, L. Yang, S. McCall et al., “Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis,” Hepatology, vol. 45, no. 6, pp. 1366–1374, 2007. View at Publisher · View at Google Scholar · View at Scopus
  85. M. Monetti, M. C. Levin, M. J. Watt et al., “Dissociation of hepatic steatosis and insulin resistance in mice overexpressing dgat in the liver,” Cell Metabolism, vol. 6, no. 1, pp. 69–78, 2007. View at Publisher · View at Google Scholar · View at Scopus
  86. F. R. Jornayvaz, A. L. Birkenfeld, M. J. Jurczak et al., “Hepatic insulin resistance in mice with hepatic overexpression of diacylglycerol acyltransferase 2,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 14, pp. 5748–5752, 2011. View at Publisher · View at Google Scholar · View at Scopus
  87. A. R. Kimmel, D. L. Brasaemle, M. McAndrews-Hill, C. Sztalryd, and C. Londos, “Adoption of PERILIPIN as a unifying nomenclature for the mammalian PAT-family of intracellular lipid storage droplet proteins,” Journal of Lipid Research, vol. 51, no. 3, pp. 468–471, 2010. View at Publisher · View at Google Scholar · View at Scopus
  88. A. S. Greenberg, J. J. Egan, S. A. Wek, N. B. Garty, E. J. Blanchette-Mackie, and C. Londos, “Perilipin, a major hormonally regulated adipocyte-specific phosphoprotein associated with the periphery of lipid storage droplets,” Journal of Biological Chemistry, vol. 266, no. 17, pp. 11341–11346, 1991. View at Google Scholar · View at Scopus
  89. H. Fujii, Y. Ikura, J. Arimoto et al., “Expression of perilipin and adipophilin in nonalcoholic fatty liver disease; relevance to oxidative injury and hepatocyte ballooning,” Journal of Atherosclerosis and Thrombosis, vol. 16, no. 6, pp. 893–901, 2009. View at Google Scholar · View at Scopus
  90. L. M. Pawella, M. Hashani, E. Eiteneuer et al., “Perilipin discerns chronic from acute hepatocellular steatosis,” Journal of Hepatology, vol. 60, no. 3, pp. 633–642, 2013. View at Publisher · View at Google Scholar
  91. H. W. Heid, R. Moll, I. Schwetlick, H.-R. Rackwitz, and T. W. Keenan, “Adipophilin is a specific marker of lipid accumulation in diverse cell types and diseases,” Cell and Tissue Research, vol. 294, no. 2, pp. 309–321, 1998. View at Publisher · View at Google Scholar · View at Scopus
  92. W. Motomura, M. Inoue, T. Ohtake et al., “Up-regulation of ADRP in fatty liver in human and liver steatosis in mice fed with high fat diet,” Biochemical and Biophysical Research Communications, vol. 340, no. 4, pp. 1111–1118, 2006. View at Publisher · View at Google Scholar · View at Scopus
  93. B. H.-J. Chang, L. Li, A. Paul et al., “Protection against fatty liver but normal adipogenesis in mice lacking adipose differentiation-related protein,” Molecular and Cellular Biology, vol. 26, no. 3, pp. 1063–1076, 2006. View at Publisher · View at Google Scholar · View at Scopus
  94. J. L. McManaman, E. S. Bales, D. J. Orlicky et al., “Perilipin-2-null mice are protected against diet-induced obesity, adipose inflammation, and fatty liver disease,” The Journal of Lipid Research, vol. 54, no. 5, pp. 1346–1359, 2013. View at Google Scholar
  95. B. H.-J. Chang, L. Li, P. Saha, and L. Chan, “Absence of adipose differentiation related protein upregulates hepatic VLDL secretion, relieves hepatosteatosis, and improves whole body insulin resistance in leptin-deficient mice,” Journal of Lipid Research, vol. 51, no. 8, pp. 2132–2142, 2010. View at Publisher · View at Google Scholar · View at Scopus
  96. Y. Imai, S. Boyle, G. M. Varela et al., “Effects of perilipin 2 antisense oligonucleotide treatment on hepatic lipid metabolism and gene expression,” Physiological Genomics, vol. 44, no. 22, pp. 1125–1131, 2012. View at Google Scholar
  97. G. M. Varela, D. A. Antwi, R. Dhir et al., “Inhibition of ADRP prevents diet-induced insulin resistance,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 295, no. 3, pp. G621–G628, 2008. View at Publisher · View at Google Scholar · View at Scopus
  98. H. Li, Y. Song, L. J. Zhang et al., “LSDP5 enhances triglyceride storage in hepatocytes by influencing lipolysis and fatty acid beta-oxidation of lipid droplets,” PLoS ONE, vol. 7, no. 6, Article ID e36712, 2012. View at Google Scholar
  99. V. Puri, S. Ranjit, S. Konda et al., “Cidea is associated with lipid droplets and insulin sensitivity in humans,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 22, pp. 7833–7838, 2008. View at Publisher · View at Google Scholar · View at Scopus
  100. L. Zhou, L. Xu, J. Ye et al., “Cidea promotes hepatic steatosis by sensing dietary fatty acids,” Hepatology, vol. 56, no. 1, pp. 95–107, 2012. View at Google Scholar
  101. Y. Jinno, M. Nakakuki, A. Sato et al., “Cide-a and Cide-c are induced in the progression of hepatic steatosis and inhibited by eicosapentaenoic acid,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 83, no. 2, pp. 75–81, 2010. View at Publisher · View at Google Scholar · View at Scopus
  102. A. M. Hall, E. M. Brunt, S. Klein, and B. N. Finck, “Hepatic expression of cell death-inducing DFFA-like effector C in obese subjects is reduced by marked weight loss,” Obesity, vol. 18, no. 2, pp. 417–419, 2010. View at Publisher · View at Google Scholar · View at Scopus
  103. Z. Zhou, S. Y. Toh, Z. Chen et al., “Cidea-deficient mice have lean phenotype and are resistant to obesity,” Nature Genetics, vol. 35, no. 1, pp. 49–56, 2003. View at Google Scholar · View at Scopus
  104. J. Z. Li, J. Ye, B. Xue et al., “Cideb regulates diet-induced obesity, liver steatosis, and insulin sensitivity by controlling lipogenesis and fatty acid oxidation,” Diabetes, vol. 56, no. 10, pp. 2523–2532, 2007. View at Publisher · View at Google Scholar · View at Scopus
  105. J. Ye, J. Z. Li, Y. Liu et al., “Cideb, an ER- and lipid droplet-associated protein, mediates vldl lipidation and maturation by interacting with apolipoprotein B,” Cell Metabolism, vol. 9, no. 2, pp. 177–190, 2009. View at Publisher · View at Google Scholar · View at Scopus
  106. Z. Chen, J. Y. Norris, and B. N. Finck, “Peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) stimulates VLDL assembly through activation of cell death-inducing DFFA-like effector B (CideB),” Journal of Biological Chemistry, vol. 285, no. 34, pp. 25996–26004, 2010. View at Publisher · View at Google Scholar · View at Scopus
  107. S. Tiwari, S. Siddiqi, and S. A. Siddiqi, “CideB protein is required for the biogenesis of very low density lipoprotein (VLDL) transport vesicle,” The Journal of Biological Chemistry, vol. 288, no. 7, pp. 5157–5165, 2013. View at Google Scholar
  108. X. Li, J. Ye, L. Zhou et al., “Opposing roles of cell death-inducing DFF45-like effector B and perilipin 2 in controlling hepatic VLDL lipidation,” The Journal of Lipid Research, vol. 53, no. 9, pp. 1877–1889, 2012. View at Google Scholar
  109. U. Danesch, W. Hoeck, and G. M. Ringold, “Cloning and transcriptional regulation of a novel adipocyte-specific gene, FSP27. CAAT-enhancer-binding protein (C/EBP) and C/EBP-like proteins interact with sequences required for differentiation-dependent expression,” Journal of Biological Chemistry, vol. 267, no. 10, pp. 7185–7193, 1992. View at Google Scholar · View at Scopus
  110. K. Matsusue, T. Kusakabe, T. Noguchi et al., “Hepatic steatosis in leptin-deficient mice is promoted by the PPARγ target gene Fsp27,” Cell Metabolism, vol. 7, no. 4, pp. 302–311, 2008. View at Publisher · View at Google Scholar · View at Scopus
  111. S. Yu, K. Matsusue, P. Kashireddy et al., “Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor γ1 (PPARγ1) overexpression,” Journal of Biological Chemistry, vol. 278, no. 1, pp. 498–505, 2003. View at Publisher · View at Google Scholar · View at Scopus
  112. N. Guillén, M. A. Navarro, C. Arnal et al., “Microarray analysis of hepatic gene expression identifies new genes involved in steatotic liver,” Physiological Genomics, vol. 37, no. 3, pp. 187–198, 2009. View at Publisher · View at Google Scholar · View at Scopus
  113. F. Yu, L. Su, S. Ji et al., “Inhibition of hepatic stellate cell activation and liver fibrosis by fat-specific protein 27,” Molecular and Cellular Biochemistry, vol. 369, no. 1-2, pp. 35–43, 2012. View at Google Scholar
  114. A. J. Hoy, C. R. Bruce, S. M. Turpin, A. J. Morris, M. A. Febbraio, and M. J. Watt, “Adipose triglyceride lipase-null mice are resistant to high-fat diet-induced insulin resistance despite reduced energy expenditure and ectopic lipid accumulation,” Endocrinology, vol. 152, no. 1, pp. 48–58, 2011. View at Publisher · View at Google Scholar · View at Scopus
  115. J. W. Wu, S. P. Wang, F. Alvarez et al., “Deficiency of liver adipose triglyceride lipase in mice causes progressive hepatic steatosis,” Hepatology, vol. 54, no. 1, pp. 122–132, 2011. View at Publisher · View at Google Scholar · View at Scopus
  116. S. M. Turpin, A. J. Hoy, R. D. Brown et al., “Adipose triacylglycerol lipase is a major regulator of hepatic lipid metabolism but not insulin sensitivity in mice,” Diabetologia, vol. 54, no. 1, pp. 146–156, 2011. View at Publisher · View at Google Scholar · View at Scopus
  117. K. T. Ong, M. T. Mashek, S. Y. Bu, and D. G. Mashek, “Hepatic ATGL knockdown uncouples glucose intolerance from liver TAG accumulation,” The FASEB Journal, vol. 27, no. 1, pp. 313–321, 2013. View at Google Scholar
  118. P. Jha, T. Claudel, A. Baghdasaryan et al., “Role of adipose triglyceride lipase (PNPLA2) in protection from hepatic inflammation in mouse models of steatohepatitis and endotoxemia,” Hepatology, vol. 59, no. 3, pp. 858–869, 2014. View at Publisher · View at Google Scholar
  119. A. Natali, A. Gastaldelli, S. Camastra et al., “Metabolic consequences of adipose triglyceride lipase deficiency in humans: an in vivo study in patients with neutral lipid storage disease with myopathy,” The Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 9, pp. E1540–E1548, 2013. View at Google Scholar
  120. B. N. Reid, G. P. Ables, O. A. Otlivanchik et al., “Hepatic overexpression of hormone-sensitive lipase and adipose triglyceride lipase promotes fatty acid oxidation, stimulates direct release of free fatty acids, and ameliorates steatosis,” Journal of Biological Chemistry, vol. 283, no. 19, pp. 13087–13099, 2008. View at Publisher · View at Google Scholar · View at Scopus
  121. K. T. Ong, M. T. Mashek, S. Y. Bu, A. S. Greenberg, and D. G. Mashek, “Adipose triglyceride lipase is a major hepatic lipase that regulates triacylglycerol turnover and fatty acid signaling and partitioning,” Hepatology, vol. 53, no. 1, pp. 116–126, 2011. View at Publisher · View at Google Scholar · View at Scopus
  122. T. C. Leone, C. J. Weinheimer, and D. P. Kelly, “A critical role for the peroxisome proliferator-activated receptor α (PPARα) in the cellular fasting response: the PPARα-null mouse as a model of fatty acid oxidation disorders,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 13, pp. 7473–7478, 1999. View at Publisher · View at Google Scholar · View at Scopus
  123. K. Harada, W.-J. Shen, S. Patel et al., “Resistance to high-fat diet-induced obesity and altered expression of adipose-specific genes in HSL-deficient mice,” American Journal of Physiology—Endocrinology and Metabolism, vol. 285, no. 6, pp. E1182–E1195, 2003. View at Google Scholar · View at Scopus
  124. S. J. Yeaman, “Hormone-sensitive lipase—new roles for an old enzyme,” Biochemical Journal, vol. 379, no. 1, pp. 11–22, 2004. View at Publisher · View at Google Scholar · View at Scopus
  125. S.-Y. Park, H.-J. Kim, S. Wang et al., “Hormone-sensitive lipase knockout mice have increased hepatic insulin sensitivity and are protected from short-term diet-induced insulin resistance in skeletal muscle and heart,” American Journal of Physiology—Endocrinology and Metabolism, vol. 289, no. 1, pp. E30–E39, 2005. View at Publisher · View at Google Scholar · View at Scopus
  126. P. J. Voshol, G. Haemmerle, D. M. Ouwens et al., “Increased hepatic insulin sensitivity together with decreased hepatic triglyceride stores in hormone-sensitive lipase-deficient mice,” Endocrinology, vol. 144, no. 8, pp. 3456–3462, 2003. View at Publisher · View at Google Scholar · View at Scopus
  127. U. Taschler, F. P. W. Radner, C. Heier et al., “Monoglyceride lipase deficiency in mice impairs lipolysis and attenuates diet-induced insulin resistance,” Journal of Biological Chemistry, vol. 286, no. 20, pp. 17467–17477, 2011. View at Publisher · View at Google Scholar · View at Scopus
  128. Z. Cao, M. M. Mulvihill, P. Mukhopadhyay et al., “Monoacylglycerol lipase controls endocannabinoid and eicosanoid signaling and hepatic injury in mice,” Gastroenterology, vol. 144, no. 4, pp. 808.e15–817.e15, 2013. View at Google Scholar
  129. S. Romeo, J. Kozlitina, C. Xing et al., “Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease,” Nature Genetics, vol. 40, no. 12, pp. 1461–1465, 2008. View at Publisher · View at Google Scholar · View at Scopus
  130. V. Nobili, G. Bedogni, B. Donati, A. Alisi, and L. Valenti, “The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-alcoholic fatty liver disease,” Journal of Medicinal Food, vol. 16, no. 10, pp. 957–960, 2013. View at Google Scholar
  131. Y. Rotman, C. Koh, J. M. Zmuda, D. E. Kleiner, and T. J. Liang, “The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease,” Hepatology, vol. 52, no. 3, pp. 894–903, 2010. View at Publisher · View at Google Scholar · View at Scopus
  132. S. Sookoian, G. O. Castaño, A. L. Burgueño, T. F. Gianotti, M. S. Rosselli, and C. J. Pirola, “A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity,” Journal of Lipid Research, vol. 50, no. 10, pp. 2111–2116, 2009. View at Publisher · View at Google Scholar · View at Scopus
  133. S. Sookoian and C. J. Pirola, “Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease,” Hepatology, vol. 53, no. 6, pp. 1883–1894, 2011. View at Publisher · View at Google Scholar · View at Scopus
  134. L. Valenti, A. Al-Serri, A. K. Daly et al., “Homozygosity for the patatin-like phospholipase-3/adiponutrin i148m polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease,” Hepatology, vol. 51, no. 4, pp. 1209–1217, 2010. View at Publisher · View at Google Scholar · View at Scopus
  135. L. Valenti, P. Dongiovanni, S. Ginanni Corradini, M. A. Burza, and S. Romeo, “PNPLA3 I148M variant and hepatocellular carcinoma: a common genetic variant for a rare disease,” Digestive and Liver Disease, vol. 45, no. 8, pp. 619–624, 2013. View at Google Scholar
  136. L. Valenti, P. Maggioni, A. Piperno et al., “Patatin-like phospholipase domain containing-3 gene I148M polymorphism, steatosis, and liver damage in hereditary hemochromatosis,” World Journal of Gastroenterology, vol. 18, no. 22, pp. 2813–2820, 2012. View at Google Scholar
  137. Y. Huang, S. He, J. Z. Li et al., “A feed-forward loop amplifies nutritional regulation of PNPLA3,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 17, pp. 7892–7897, 2010. View at Publisher · View at Google Scholar · View at Scopus
  138. M. Hoekstra, Z. Li, J. K. Kruijt, M. V. Eck, T. J. C. V. Berkel, and J. Kuiper, “The expression level of non-alcoholic fatty liver disease-related gene PNPLA3 in hepatocytes is highly influenced by hepatic lipid status,” Journal of Hepatology, vol. 52, no. 2, pp. 244–251, 2010. View at Publisher · View at Google Scholar · View at Scopus
  139. W. Chen, B. Chang, L. Li, and L. Chan, “Patatin-like phospholipase domain-containing 3/adiponutrin deficiency in mice is not associated with fatty liver disease,” Hepatology, vol. 52, no. 3, pp. 1134–1142, 2010. View at Publisher · View at Google Scholar · View at Scopus
  140. Y. Huang, J. C. Cohen, and H. H. Hobbs, “Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease,” Journal of Biological Chemistry, vol. 286, no. 43, pp. 37085–37093, 2011. View at Publisher · View at Google Scholar · View at Scopus
  141. J. Z. Li, Y. Huang, R. Karaman et al., “Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis,” The Journal of Clinical Investigation, vol. 122, no. 11, pp. 4130–4144, 2012. View at Google Scholar
  142. S. Mudaliar, R. R. Henry, A. J. Sanyal et al., “Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease,” Gastroenterology, vol. 145, no. 3, pp. 574.e1–582.e1, 2013. View at Google Scholar
  143. M. Péterfy, J. Phan, P. Xu, and K. Reue, “Lipodystrophy in the fld mouse results from mutation of a new gene encoding a nuclear protein, lipin,” Nature Genetics, vol. 27, no. 1, pp. 121–124, 2001. View at Publisher · View at Google Scholar · View at Scopus
  144. K. Reue, P. Xu, X.-P. Wang, and B. G. Slavin, “Adipose tissue deficiency, glucose intolerance, and increased atherosclerosis result from mutation in the mouse fatty liver dystrophy (fld) gene,” Journal of Lipid Research, vol. 41, no. 7, pp. 1067–1076, 2000. View at Google Scholar · View at Scopus
  145. L. S. Csaki, J. R. Dwyer, X. Li et al., “Lipin-1 and lipin-3 together determine adiposity in vivo,” Molecular Metabolism, vol. 3, no. 2, pp. 145–154, 2014. View at Google Scholar